Tags » Outcomes Research

PD-1 inhibitors – making immuno-oncology mainstream?

The world’s first Programmed cell death 1 (PD-1) inhibitor was approved in Japan this month for the treatment of advanced melanoma. This novel class of investigational immuno-oncology drugs continues to receive considerable attention and interest globally – particularly at this year’s annual… 520 more words

Outcomes & Research

Economics of the Obesity Epidemic - Extracting Knowledge with Advanced Text Analytics

In the current competitive marketplace for healthcare, pharmaceutical and medical technology companies must be able to demonstrate clinical and economic evidence of benefit to providers, healthcare decision-makers and payers. 349 more words

Linguamatics Updates

Why is the Lucentis-Avastin case back in the spotlight?

Is Avastin as safe and effective as Lucentis in an ophthalmology setting? In recent years, many countries have evaluated potential risks posed by off-label use of the cheaper Avastin (bevacizumab) – manufactured by Roche’s US subsidiary Genentech and marketed by Novartis outside US – compared to the more expensive Genentech’s drug Lucentis (ranibizumab injection) and approved in a number of countries for the treatment of neovascular (wet) age-related macular degeneration (wet-AMD). 871 more words

Outcomes & Research